Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK.
Author
Dixon, GilesHague, Samuel
Mulholland, Sarah
Adamali, Huzaifa
Khin, Aye Myat Noe
Thould, Hannah
Connon, Roisin
Minnis, Paul
Murtagh, Eoin
Khan, Fasihul
Toor, Sameen
Lawrence, Alexandra
Naqvi, Marium
West, Alex
Coker, Robina K
Ward, Katie
Yazbeck, Leda
Hart, Simon
Garfoot, Theresa
Newman, Kate
Rivera-Ortega, Pilar
Stranks, Lachlan
Beirne, Paul
Bradley, Jessica
Rowan, Catherine
Agnew, Sarah
Ahmad, Mahin
Spencer, Lisa G
Aigbirior, Joshua
Fahim, Ahmed
Wilson, Andrew M
Butcher, Elizabeth
Chong, Sy Giin
Saini, Gauri
Zulfikar, Sabrina
Chua, Felix
George, Peter M
Kokosi, Maria
Kouranos, Vasileios
Molyneaux, Philip
Renzoni, Elisabetta
Vitri, Benedetta
Wells, Athol U
Nicol, Lisa M
Bianchi, Stephen
Kular, Raman
Liu, HuaJian
John, Alexander
Barth, Sarah
Wickremasinghe, Melissa
Forrest, Ian A
Grimes, Ian
Simpson, A John
Fletcher, Sophie V
Jones, Mark G
Kinsella, Emma
Naftel, Jennifer
Wood, Nicola
Chalmers, Jodie
Crawshaw, Anjali
Crowley, Louise E
Dosanjh, Davinder
Huntley, Christopher C
Walters, Gareth I
Gatheral, Timothy
Plum, Catherine
Bikmalla, Shiva
Muthusami, Raja
Stone, Helen
Rodrigues, Jonathan C L
Tsaneva-Atanasova, Krasimira
Scotton, Chris J
Gibbons, Michael A
Barratt, Shaney L
Publication date
2024-01-15Subject
Respiratory medicine
Metadata
Show full item recordAbstract
Background: Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service in Scotland in June 2021 and in England, Wales and Northern Ireland in November 2021. To date, there has been no national evaluation of the use of nintedanib for PF-ILD in a real-world setting. Methods: 26 UK centres were invited to take part in a national service evaluation between 17 November 2021 and 30 September 2022. Summary data regarding underlying diagnosis, pulmonary function tests, diagnostic criteria, radiological appearance, concurrent immunosuppressive therapy and drug tolerability were collected via electronic survey. Results: 24 UK prescribing centres responded to the service evaluation invitation. Between 17 November 2021 and 30 September 2022, 1120 patients received a multidisciplinary team recommendation to commence nintedanib for PF-ILD. The most common underlying diagnoses were hypersensitivity pneumonitis (298 out of 1120, 26.6%), connective tissue disease associated ILD (197 out of 1120, 17.6%), rheumatoid arthritis associated ILD (180 out of 1120, 16.0%), idiopathic nonspecific interstitial pneumonia (125 out of 1120, 11.1%) and unclassifiable ILD (100 out of 1120, 8.9%). Of these, 54.4% (609 out of 1120) were receiving concomitant corticosteroids, 355 (31.7%) out of 1120 were receiving concomitant mycophenolate mofetil and 340 (30.3%) out of 1120 were receiving another immunosuppressive/modulatory therapy. Radiological progression of ILD combined with worsening respiratory symptoms was the most common reason for the diagnosis of PF-ILD. Conclusion: We have demonstrated the use of nintedanib for the treatment of PF-ILD across a broad range of underlying conditions. Nintedanib is frequently co-prescribed alongside immunosuppressive and immunomodulatory therapy. The use of nintedanib for the treatment of PF-ILD has demonstrated acceptable tolerability in a real-world setting.Citation
Dixon G, Hague S, Mulholland S, Adamali H, Khin AMN, Thould H, Connon R, Minnis P, Murtagh E, Khan F, Toor S, Lawrence A, Naqvi M, West A, Coker RK, Ward K, Yazbeck L, Hart S, Garfoot T, Newman K, Rivera-Ortega P, Stranks L, Beirne P, Bradley J, Rowan C, Agnew S, Ahmad M, Spencer LG, Aigbirior J, Fahim A, Wilson AM, Butcher E, Chong SG, Saini G, Zulfikar S, Chua F, George PM, Kokosi M, Kouranos V, Molyneaux P, Renzoni E, Vitri B, Wells AU, Nicol LM, Bianchi S, Kular R, Liu H, John A, Barth S, Wickremasinghe M, Forrest IA, Grimes I, Simpson AJ, Fletcher SV, Jones MG, Kinsella E, Naftel J, Wood N, Chalmers J, Crawshaw A, Crowley LE, Dosanjh D, Huntley CC, Walters GI, Gatheral T, Plum C, Bikmalla S, Muthusami R, Stone H, Rodrigues JCL, Tsaneva-Atanasova K, Scotton CJ, Gibbons MA, Barratt SL. Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK. ERJ Open Res. 2024 Jan 15;10(1):00529-2023. doi: 10.1183/23120541.00529-2023.Type
ArticleAdditional Links
https://openres.ersjournals.comPMID
38226064Journal
ERJ Open ResearchPublisher
European Respiratory Societyae974a485f413a2113503eed53cd6c53
10.1183/23120541.00529-2023